A Randomized Clinical Trial with security and dose testing of Sildenafil Citrate in patients
with subarachnoid hemorrhage due to a rupture of a cerebral aneurism for prevention of
cerebral vasospasm. The cerebral vasospasm is a decrease in blood flow that occurs when the
intracranial vessels lose their capability of self-control of dilations and contractions.
Patients with subarachnoid hemorrhage without neurological deficits who underwent
endovascular or surgical correction of the aneurysm can participate in this trial. They will
be randomized to a daily doses of 75 mg of Sildenafil, 150 mg of Sildenafil or Placebo from
the third to the 14th day post bleeding. Today there is no proven clinical treatment for
prevention of cerebral vasospasm.